Federal Register Notice: FDA’s Cardiovascular and Renal Drugs Advisory Committee will meet 12/11-12, from 8 a.m. to 5 p.m. at the Sheraton College Park Hotel, 4095 Powder Mill Rd., Beltsville, MD. On 12/11, the committee will discuss an Astellas Pharma U.S. Inc. NDA for vernakalant hydrochloride injection, 20 mg/ml for conversion of atrial fibrillation to normal sinus rhythm. On 12/12 the committee will discuss Solvay’s NDA for Pulzium (tedisamil sesquifumarate) IV solution 2 mg/ml for conversion of atrial fibrillation or atrial flutter to normal sinus rhythm. Contact Cathy A. Miller, (301) 827-7001. To view this notice, click here.